We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





New Generation of Long-Acting Immunotherapeutic Antivirals Aim to Prevent COVID-19/Flu ‘Twindemics’

By HospiMedica International staff writers
Posted on 18 Sep 2020
Print article
Image: Cidara’s Cloudbreak antiviral platform is a fundamentally new approach to treating and preventing viral infections (Photo courtesy of Cidara Therapeutics, Inc.)
Image: Cidara’s Cloudbreak antiviral platform is a fundamentally new approach to treating and preventing viral infections (Photo courtesy of Cidara Therapeutics, Inc.)
A new generation of long-acting therapeutics designed for patients facing serious viral infections is aiming to prevent “twindemic” double threats of influenza and COVID-19.

Cidara Therapeutics, Inc. (San Diego, CA, USA), a biotechnology company, is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system to maximize viral clearance.

Cidara’s Cloudbreak antiviral platform is a fundamentally new approach to treating and preventing viral infections. By applying the principles of immuno-oncology to infectious disease, Cidara is creating a new generation of antivirals that stably couple a potent antiviral targeting domain, a small molecule or a peptide, to an effector domain, a proprietary variant of a human antibody fragment (Fc). These long-acting, bispecific AVCs are designed to directly inhibit viral proliferation while simultaneously directing immune-mediated clearance of the virus. The two distinct and complementary mechanisms are designed to maximize antiviral activity of AVCs.

Cidara is developing its lead flu candidate, CD377, to achieve universal prevention of seasonal and pandemic influenza with a single dose. As an AVC, CD377 is not a vaccine or a monoclonal antibody. Its targeting domains are small molecule antivirals that bind to a highly conserved target on the influenza cell surface, which is essential for viral proliferation and enables universal influenza coverage. With this mechanism, CD377 has the potential for universal coverage of influenza A and B, as well as all major clinically characterized drug-resistant strains. CD377 has the potential to offer significant advantages over the current flu vaccine such as true universal protection, against all influenza strains and for all people, including those with a compromised immune system; and near-immediate protective effects

In preclinical studies, CD377 demonstrated that a single subcutaneous dose was highly potent against strains of influenza responsible for pandemics in a lethal influenza mouse model. A single dose of CD377 demonstrated potential for long-term protection in mice subjected to pandemic strains of influenza. Single 0.1 mg/kg intravenous (IV), intramuscular (IM) and subcutaneous (SC) doses of CD377 afforded equivalent protection in mice dosed two hours post infection. CD377 also demonstrated a lower resistance potential compared to approved influenza treatments, baloxavir and oseltamivir, against a pandemic strain of influenza. CD377 extended the treatment window, demonstrating improved efficacy with a single dose three days post-infection compared to multiple doses of oseltamivir starting at three days post-infection in a lethal influenza mouse model. Additionally, a single dose of CD377 was immediately elevated in both plasma and epithelial lining fluid (ELF) of the respiratory tract in mice. Cidara is currently conducting studies in support of an investigational new drug application for CD377 for influenza prevention in order to begin Phase 1 clinical trials.

Related Links:
Cidara Therapeutics, Inc.

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Critical Care Trolley
CCT-PX

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.